These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 32795424)

  • 21. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).
    Agarwal A; Mukherjee A; Kumar G; Chatterjee P; Bhatnagar T; Malhotra P;
    BMJ; 2020 Oct; 371():m3939. PubMed ID: 33093056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq.
    Rasheed AM; Fatak DF; Hashim HA; Maulood MF; Kabah KK; Almusawi YA; Abdulamir AS
    Infez Med; 2020 Sep; 28(3):357-366. PubMed ID: 32920571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.
    Bradfute SB; Hurwitz I; Yingling AV; Ye C; Cheng Q; Noonan TP; Raval JS; Sosa NR; Mertz GJ; Perkins DJ; Harkins MS
    J Infect Dis; 2020 Oct; 222(10):1620-1628. PubMed ID: 32779705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series.
    Zeng H; Wang D; Nie J; Liang H; Gu J; Zhao A; Xu L; Lang C; Cui X; Guo X; Zhou C; Li H; Guo B; Zhang J; Wang Q; Fang L; Liu W; Huang Y; Mao W; Chen Y; Zou Q
    Signal Transduct Target Ther; 2020 Oct; 5(1):219. PubMed ID: 33024082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile.
    Sturek JM; Thomas TA; Gorham JD; Sheppard CA; Raymond AH; Petros De Guex K; Harrington WB; Barros AJ; Madden GR; Alkabab YM; Lu DY; Liu Q; Poulter MD; Mathers AJ; Thakur A; Schalk DL; Kubicka EM; Lum LG; Heysell SK
    Microbiol Spectr; 2022 Feb; 10(1):e0256021. PubMed ID: 35196802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19.
    Hueso T; Pouderoux C; Péré H; Beaumont AL; Raillon LA; Ader F; Chatenoud L; Eshagh D; Szwebel TA; Martinot M; Camou F; Crickx E; Michel M; Mahevas M; Boutboul D; Azoulay E; Joseph A; Hermine O; Rouzaud C; Faguer S; Petua P; Pommeret F; Clerc S; Planquette B; Merabet F; London J; Zeller V; Ghez D; Veyer D; Ouedrani A; Gallian P; Pacanowski J; Mékinian A; Garnier M; Pirenne F; Tiberghien P; Lacombe K
    Blood; 2020 Nov; 136(20):2290-2295. PubMed ID: 32959052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China.
    Li L; Yang R; Wang J; Lv Q; Ren M; Zhao L; Chen H; Xu H; Xie S; Xie J; Lin H; Li W; Fang P; Gong L; Wang L; Wu Y; Liu Z
    Transfusion; 2020 Aug; 60(8):1773-1777. PubMed ID: 32491199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study.
    Rojas M; Rodríguez Y; Hernández JC; Díaz-Coronado JC; Vergara JAD; Vélez VP; Mancilla JP; Araujo I; Yepes JT; Ricaurte OB; Pardo-Oviedo JM; Monsalve DM; Acosta-Ampudia Y; Ramírez-Santana C; García PG; Landinez LA; Correales LD; Grass JS; Pérez CR; López GS; Mateus N; Mancera L; Devia RR; Orjuela JE; Parra-Moreno CR; Buitrago AA; Ordoñez IE; Osorio CF; Ballesteros N; Patiño LH; Castañeda S; Muñoz M; Ramírez JD; Bastard P; Gervais A; Bizien L; Casanova JL; Camacho B; Gallo JE; Gómez O; Rojas-Villarraga A; Pérez CE; Manrique R; Mantilla RD; Anaya JM
    BMC Infect Dis; 2022 Jun; 22(1):575. PubMed ID: 35761219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Convalescent plasma therapy in COVID-19 patients, in the Province of Buenos Aires].
    González SE; Regairaz L; Ferrando NS; González Martínez VV; Salazar MR; Estenssoro E
    Medicina (B Aires); 2020; 80(5):417-424. PubMed ID: 33048783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of convalescent plasma therapy in severe COVID-19 patients.
    Duan K; Liu B; Li C; Zhang H; Yu T; Qu J; Zhou M; Chen L; Meng S; Hu Y; Peng C; Yuan M; Huang J; Wang Z; Yu J; Gao X; Wang D; Yu X; Li L; Zhang J; Wu X; Li B; Xu Y; Chen W; Peng Y; Hu Y; Lin L; Liu X; Huang S; Zhou Z; Zhang L; Wang Y; Zhang Z; Deng K; Xia Z; Gong Q; Zhang W; Zheng X; Liu Y; Yang H; Zhou D; Yu D; Hou J; Shi Z; Chen S; Chen Z; Zhang X; Yang X
    Proc Natl Acad Sci U S A; 2020 Apr; 117(17):9490-9496. PubMed ID: 32253318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: a case report.
    Xu TM; Lin B; Chen C; Liu LG; Xue Y
    Virol J; 2020 Jun; 17(1):80. PubMed ID: 32560646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Convalescent plasma to treat COVID-19.
    Bloch EM
    Blood; 2020 Aug; 136(6):654-655. PubMed ID: 32761219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COVID-19 convalescent plasma: phase 2.
    Knudson CM; Jackson JB
    Transfusion; 2020 Jun; 60(6):1332-1333. PubMed ID: 32374890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Convalescent plasma therapy for COVID-19: a tried-and-true old strategy?
    Xi Y
    Signal Transduct Target Ther; 2020 Sep; 5(1):203. PubMed ID: 32934211
    [No Abstract]   [Full Text] [Related]  

  • 37. Analysis of COVID-19 convalescent plasma for SARS-CoV-2 IgG using two commercial immunoassays.
    DomBourian MG; Annen K; Huey L; Andersen G; Merkel PA; Jung S; Dominguez SR; Knight V
    J Immunol Methods; 2020 Nov; 486():112837. PubMed ID: 32828791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea.
    Ahn JY; Sohn Y; Lee SH; Cho Y; Hyun JH; Baek YJ; Jeong SJ; Kim JH; Ku NS; Yeom JS; Roh J; Ahn MY; Chin BS; Kim YS; Lee H; Yong D; Kim HO; Kim S; Choi JY
    J Korean Med Sci; 2020 Apr; 35(14):e149. PubMed ID: 32281317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Convalescent plasma treatment for COVID-19: Tempering expectations with the influenza experience.
    Subbarao K; Mordant F; Rudraraju R
    Eur J Immunol; 2020 Oct; 50(10):1447-1453. PubMed ID: 32886952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Retrospective Study on the Effects of Convalescent Plasma Therapy in 24 Patients Diagnosed with COVID-19 Pneumonia in February and March 2020 at 2 Centers in Wuhan, China.
    Huang S; Shen C; Xia C; Huang X; Fu Y; Tian L
    Med Sci Monit; 2020 Dec; 26():e928755. PubMed ID: 33264276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.